Previous 10 | Next 10 |
-- Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) -- -- Novel combination aims to leverage the macrophage component of the innate immune system and a targeted kinase inhibitor -- MENLO PARK, Calif., May 10, 2019 (G...
MENLO PARK, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 4:30 p....
MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage company immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced an extension of its agreement with Genentech, a member...
Forty Seven, Inc. (FTSV) Q4 2018 Results Earnings Conference Call March 28, 2019, 04:30 AM ET Company Participants Hannah Deresiewicz - Investor Relations Mark McCamish - President and Chief Executive Officer Ann Rhoads - Chief Financial Officer Chris Takimoto - Chief Medical O...
Forty Seven (NASDAQ: FTSV ): Q4 GAAP EPS of -$0.56 beats by $0.09 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in Second Quarter of 2019 – -- Updated Data from Phase 1b Trial of 5F9 as a Monotherapy and in Combination with Azacitidine in Acute M...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp ...
MENLO PARK, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 4:30 ...
The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...